WO2002030469A3 - Beta-lactam antibiotic-polysaccharide complex - Google Patents

Beta-lactam antibiotic-polysaccharide complex Download PDF

Info

Publication number
WO2002030469A3
WO2002030469A3 PCT/IN2001/000179 IN0100179W WO0230469A3 WO 2002030469 A3 WO2002030469 A3 WO 2002030469A3 IN 0100179 W IN0100179 W IN 0100179W WO 0230469 A3 WO0230469 A3 WO 0230469A3
Authority
WO
WIPO (PCT)
Prior art keywords
beta
lactam
lactam antibiotic
polysaccharide complex
antibiotics
Prior art date
Application number
PCT/IN2001/000179
Other languages
French (fr)
Other versions
WO2002030469A2 (en
Inventor
Prasanta Kumar Chakrabarti
Canakapalli Bhaktavatsala Rao
Original Assignee
Orchid Chemicals & Pharm Ltd
Prasanta Kumar Chakrabarti
Canakapalli Bhaktavatsala Rao
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orchid Chemicals & Pharm Ltd, Prasanta Kumar Chakrabarti, Canakapalli Bhaktavatsala Rao filed Critical Orchid Chemicals & Pharm Ltd
Priority to AU2002215180A priority Critical patent/AU2002215180A1/en
Publication of WO2002030469A2 publication Critical patent/WO2002030469A2/en
Publication of WO2002030469A3 publication Critical patent/WO2002030469A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention provides novel Beta-lactam antibiotic-polysaccharide complexes having a lower dose of active moiety resulting in equal pharmacological and microbiological response compared to respective parent drugs, leading to lesser toxicity and reduced cost of treatment for the patients and also, the invention provides a process for the production of novel compositions containing Beta-lactam antibiotics, said process comprising the steps of reacting Beta-lactam ring containing antibiotics with polysaccharides in the presence of a solvent, and lyophilisation of the complex under vacuum.
PCT/IN2001/000179 2000-10-12 2001-10-11 Beta-lactam antibiotic-polysaccharide complex WO2002030469A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002215180A AU2002215180A1 (en) 2000-10-12 2001-10-11 Beta-lactam antibiotic-polysaccharide complex

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN730MA1999 2000-10-12
IN729/MAS/1999 2000-10-12
IN729MA1999 2000-10-12
IN730/MAS/1999 2000-10-12

Publications (2)

Publication Number Publication Date
WO2002030469A2 WO2002030469A2 (en) 2002-04-18
WO2002030469A3 true WO2002030469A3 (en) 2003-02-27

Family

ID=26324828

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2001/000179 WO2002030469A2 (en) 2000-10-12 2001-10-11 Beta-lactam antibiotic-polysaccharide complex

Country Status (2)

Country Link
AU (1) AU2002215180A1 (en)
WO (1) WO2002030469A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013025783A2 (en) * 2011-08-15 2013-02-21 Gentle Thomas M Water soluble antimicrobial composition
US8815952B1 (en) 2013-03-15 2014-08-26 Carnell & Herzog, LLC Chlorhexadine antiseptic
CN104382864A (en) * 2014-08-29 2015-03-04 四川制药制剂有限公司 Processing technology of ceftriaxone sodium for injection
CN106279208A (en) * 2016-08-15 2017-01-04 陕西顿斯制药有限公司 A kind of cefotaxime sodium compound utilizing fluid mechanics principle to prepare and preparation thereof
CN113842365B (en) * 2021-10-28 2022-10-28 海南海灵化学制药有限公司 Preparation process of cefazolin sodium for injection

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4489065A (en) * 1981-07-02 1984-12-18 Valcor Scientific Ltd. Chondroitin drug Complexes
WO1992017167A1 (en) * 1991-04-02 1992-10-15 Biotech Australia Pty. Ltd. Oral delivery systems for microparticles
WO1998016253A1 (en) * 1996-10-15 1998-04-23 Ebara Corporation Bioactive polymer product
WO1999015150A1 (en) * 1997-09-22 1999-04-01 Buford Biomedical, Inc. Inorganic-polymer complexes for the controlled release of compounds including medicinals
WO2000078287A1 (en) * 1999-05-18 2000-12-28 Istituto Biochimico Pavese Pharma S.P.A. Antibiotic-natural polysaccharide polymer adducts
WO2001097851A2 (en) * 2000-06-21 2001-12-27 Cubist Pharmaceuticals, Inc. Compositions and methods to improve the oral absorption of antimicrobial agents

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4489065A (en) * 1981-07-02 1984-12-18 Valcor Scientific Ltd. Chondroitin drug Complexes
WO1992017167A1 (en) * 1991-04-02 1992-10-15 Biotech Australia Pty. Ltd. Oral delivery systems for microparticles
WO1998016253A1 (en) * 1996-10-15 1998-04-23 Ebara Corporation Bioactive polymer product
WO1999015150A1 (en) * 1997-09-22 1999-04-01 Buford Biomedical, Inc. Inorganic-polymer complexes for the controlled release of compounds including medicinals
WO2000078287A1 (en) * 1999-05-18 2000-12-28 Istituto Biochimico Pavese Pharma S.P.A. Antibiotic-natural polysaccharide polymer adducts
WO2001097851A2 (en) * 2000-06-21 2001-12-27 Cubist Pharmaceuticals, Inc. Compositions and methods to improve the oral absorption of antimicrobial agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MOLTENI L.: "Dextran and inulin conjugates as drug carriers.", METHODS IN ENZYMOLOGY, (1985) VOL. 112/- (285-298). CODEN: MENZAU, XP008004814 *

Also Published As

Publication number Publication date
WO2002030469A2 (en) 2002-04-18
AU2002215180A1 (en) 2002-04-22

Similar Documents

Publication Publication Date Title
CA2148928A1 (en) Pharmacologically active pyridine derivatives and processes for the preparation thereof
CA2123363A1 (en) Lysosomal enzyme-cleavable antitumor drug conjugates
GEP20032967B (en) Indolyl-3-Glyoxylic Acid Derivatives As an Antitumor Agent and Pharmaceutical Composition
FI942075A0 (en) Tetrazole derivatives of bile acids, process for their preparation and use of these compounds as drugs
WO2004041153A3 (en) Pharmaceutical composition including low dosages of desmopressin
WO2001046200A8 (en) Novel piperidine and piperazine derivatives
CA2127111A1 (en) A Method for Preparing Enteric-Coated Oral Drugs Containing Acid-Unstable Compounds
WO2003013541A8 (en) 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives
WO2003061577A3 (en) Polyalkylene glycol with moiety for conjugating biologically active compound
HUT62466A (en) Process for producing locally applicable pharmaceutical compositions comprising allylamine derivatives, against fungus infection
CA2386775A1 (en) Drugs for the treatment of malignant tumours
WO2002008194A8 (en) Novel heteroaryl derivatives and the use thereof as pharmaceuticals
AU5812400A (en) Carrier-drug conjugate
CA2145826A1 (en) Lipopeptide derivatives, a process for their preparation and their use
IL117091A0 (en) Methylphenyloxazolidinone derivatives pharmaceutical compositions containing the same and processes for the preparation thereof
DE602004011966D1 (en) Heterocyclylverbindungen
EP0388956A3 (en) Phthalinide derivative, pharmaceutical composition and use
WO2002030469A3 (en) Beta-lactam antibiotic-polysaccharide complex
NO177714C (en) Analogous Process for Preparing Therapeutically Active Peptide Derivatives
IL97795A0 (en) Cycloalkano(b)dihydroindoles and-indolesulphonamides substituted by heterocycles,their preparation and pharmaceutical compositions containing them
HRP930014B1 (en)
WO2001030391A3 (en) Pharmaceutical composition containing midazolam
EP0627436A4 (en) Carcinostatic compound and production thereof.
FUJII et al. UCE1022, a new antitumor antibiotic with topoisomerase I mediated DNA cleavage activity, from Paecilomyces
EP1059304A4 (en) Novel polysaccharide derivatives, process for the production thereof and medicinal compositions containing the same as the active ingredient

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)